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Abstract 
BACKGROUND: The durable polymer drug-eluting stents (DPDES) reduce the risk of repeated target vessel 
revascularisation (TLR) compared with BMS, but are associated with increased risk of late adverse events. In 
broadly inclusive populations, the biodegradable-polymer drug-eluting stents (BPDES) have favourable results 
compared with DPDES in the long term. However, its use in primary angioplasty has not been adequately studied, 
and data of real-world clinical experience is lacking.  
AIM: Aim of this study was to assess the safety and efficacy of Yukon Choice PC Elite sirolimus-eluting stent (a 
novel BPDES) in STEMI patients undergoing primary angioplasty. 
METHODS: We have presented here one-year clinical follow-up data of the Yukon Choice PC Elite sirolimus-
eluting stent in patients undergoing primary angioplasty. A total of 636 patients were enrolled in this single arm, 
prospective observational study from five centres.  
RESULTS: This multicentric observational study showed excellent safety and efficacy profile of the novel device 
at one year follow up. The device-oriented composite endpoint (DOCE) of cardiac death, target-vessel 
reinfarction, and target-lesion revascularisation (TLR) was 2.7%, and the patient-oriented composite endpoint 
(POCE) of all-cause death, any myocardial infarction, and any revascularisation was 4.2% at one year. Definite or 
probable stent thrombosis rate was 0.6%, and no events were recorded beyond 6 months of follow up.  
CONCLUSIONS: In patients with STEMI undergoing primary angioplasty, the use of Yukon Choice PC Elite 
(biodegradable polymer sirolimus-eluting stent) has excellent results at one year. It, therefore, represents an 
attractive alternative to second generation DES in this high-risk population. 
 
 
 
 
 
Introduction 
 
Primary percutaneous coronary intervention 
(PCI) is considered the gold standard of management 
in ST-segment elevation myocardial infarction 
(STEMI) [1], [2]. Coronary stenting with a bare-metal 
stent (BMS) is associated with a lower risk of 
reinfarction and target vessel revascularisation 
compared with balloon angioplasty alone [3]. The 
advent of drug-eluting stents (DES) has further 
reduced the in-stent restenosis and the risk of 
repeated target vessel revascularisation compared 
with BMS [4]. However, the first-generation DES, 
including the sirolimus and paclitaxel-eluting stents, 
have increased the risk stent thrombosis over the long 
term [5], [6].
 
These late adverse events are related to 
hypersensitivity reactions to the durable polymer 
which produces chronic inflammation and thereby 
delays endothelial healing and favour stent 
thrombosis [7], [8], [9]. This is especially important in 
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patients with STEMI because of plaque rupture, high 
thrombus burden and increased platelet activation [8], 
[10]. Moreover, there are chronic processes leading to 
delayed endothelial healing, vessel remodelling and 
stent malapposition [8], [11].  
 Second-generation DES were subsequently 
developed using thinner stent struts, more 
biocompatible polymers, and a lower dose of newer 
anti-proliferative agents (Everolimus and Zotarolimus). 
The most recent addition to the stent technology is the 
development of biodegradable polymer drug-eluting 
stents (BPDES), the third generation DES. These 
newer generation DES with more biocompatible or 
biodegradable polymer have been shown to have 
lower thrombogenicity compared to BMS in 
experimental studies [12]. However, the ideal DES for 
use in STEMI is still not clear as there is no conclusive 
evidence of superiority.  
 BP-DES degrades after completion of drug 
release and transforms functionally into BMS. This 
may improve arterial healing by removing the chronic 
source of inflammation, the durable polymer, present 
in all current second-generation DES. Consequently, 
BP-DES appears to be a novel solution for STEMI, by 
possibly reducing late ischemic events. We report 
here the one-year outcomes associated with the use 
of a novel biodegradable polymer DES, the Yukon 
Choice PC Elite sirolimus-eluting stent (Translumina 
Therapeutics, Germany), in STEMI population 
undergoing primary angioplasty. Recent studies with 
their use in all-comer populations have been 
encouraging [13], [14], [15]. However, there is a 
paucity of data regarding real world experience with 
this device in STEMI patients.  
 
 
Methods 
 
Patients 
This was a prospective observational single 
arm study from five centres across India. Patients 
presenting with STEMI were screened for inclusion in 
the study. Patients were eligible for inclusion if: (1) 
they presented within 12 hours of symptom onset, or 
between 12 hours and 24 hours if they had persistent 
symptoms with evidence of ongoing ischemia; (2) 
procedures were completed with only Yukon Choice 
PC Elite DES. Patients were excluded if they had a 
contraindication to antiplatelet or anticoagulant 
therapy, undergone CABG, pregnant women and 
women of childbearing potential and known 
hypersensitivity to sirolimus, shellac or stainless steel. 
The study was conducted according to the Helsinki 
Declaration and the Good Clinical Practice Guidelines. 
Written informed consent was obtained from each 
patient before performing the PCI procedure. 
Study Device  
The Yukon Choice PC Elite stent is a third 
generation sirolimus-eluting stent (SES) from 
Translumina Therapeutics (Germany), now being 
manufactured in India. This is made up of surgical 
grade stainless steel (87 μm strut thickness) coated 
with a biodegradable polymer (polylactic acid, PLA) 
and sirolimus, which releases from the matrix of 
Resomer 202S and Shellac resin. It has a unique 
micro-porous stent surface, PEARL surface, which 
favours better endothelialisation. The drug is coated 
only abluminally with no drug or polymer on the 
luminal side of the stent. Sirolimus eluted from the 
abluminal side controls smooth muscle cell 
proliferation, while the luminal side promotes 
endothelialisation as there is no polymer or drug (acts 
like BMS). It has the least polymeric load of a 
biodegradable polymer, 1/4
th
 of polymer present in 
conventional DES. The drug is released in 4-6 weeks, 
and polymer gets completely degraded in 60-90 days, 
and it essentially becomes a bare metal stent. 
Sirolimus has a broad therapeutic profile and flat 
dose-response curve leading to consistent and 
homogenous anti-proliferative and 
immunosuppressant properties. Sirolimus-eluting 
stents have consistently shown superior outcomes 
compared to the paclitaxel-eluting stent (PES) [16], 
[17] and zotarolimus-eluting stent (ZES) [18], whereas 
comparable safety and efficacy profile to the 
everolimus-eluting stent (EES) [19], [20]. However, 
sirolimus is temperature sensitive and get degraded at 
a temperature of > 30°C into an open-chain isomer 
(34-hydroxy sirolimus) retaining less than 10% of the 
immunosuppressive activity [21].
 
The Yukon Choice 
PC Elite is a cosmetically improved version of Yukon 
Choice PC stent, which is specially adapted for 
conditions of extreme temperatures particularly seen 
in the tropical regions. It comes with dual packing of 
the outer polystyrene box and inner aluminium pack. 
Additionally, it has a highly sensitive temperature 
monitoring device, the Tag Alert, which uses 
Sensitech Technology.  
 
Study procedure 
All the patients included in the study 
underwent loading with ticagrelor 180 mg, aspirin 300 
mg and atorvastatin 80 mg in the emergency 
department and shifted to the catheterisation 
laboratory. The radial approach was the default 
access site in all patients undergoing primary 
angioplasty. During the angioplasty procedure, 
intravenous unfractionated heparin was used for 
anticoagulation, and glycoprotein IIb/IIIa inhibitors 
were used as a bail-out. Thrombosuction was used 
only in cases with large residual thrombus burden 
after opening the culprit artery with guidewire or 
balloon. After the intervention, all patients received 
aspirin indefinitely and clopidogrel, prasugrel or 
ticagrelor for at least 12 months. Patients remained in 
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the hospital for at least 48 h. Blood samples were 
drawn every 24 h for the determination of cardiac 
markers, blood cell counts and renal function test. 
Daily recording of ECG was also performed until 
discharge.  
 
Follow up and study endpoints 
Clinical follow-up visits were scheduled at day 
14 and monthly after that up to one year. Frequent 
follow-up visits, telephonic conversation, reminder 
messages (SMS) and frequent group counselling 
sessions were organised to ensure better drug 
compliance, drug/dose adjustment and collecting data 
regarding adverse events. The primary endpoint of the 
study was device-oriented composite endpoint 
(DOCE) of cardiac death, target-vessel reinfarction, 
and target-lesion revascularisation (TLR) and the co-
primary endpoint was patient-oriented composite 
endpoint (POCE) of all-cause death, any myocardial 
infarction, and any revascularisation at the 30-day, 6 
months and 1-year of follow-up. The secondary 
endpoint of this study was the incidence of definite or 
probable stent thrombosis at the 30-day, 6 months 
and 1-year of follow-up.
 
Additional secondary 
endpoints were major/minor bleeding and TLR rates. 
 
Definitions 
Clinical device success was defined as 
successful delivery and deployment of the first 
inserted stent and final diameter stenosis after 
stenting ≤ 50% by quantitative coronary angiography 
or visual assessment. Clinical procedure success was 
defined as clinical device success without the 
occurrence of serious cardiac events important for 
ischemia during hospitalisation. Any death was 
defined as cardiac unless an unequivocal noncardiac 
cause could be established. Stent thrombosis was 
defined as acute (< 24 h), subacute (24 h to 30 days), 
late (> 30 days to 1 year), and very late (> 1 year). It 
was further defined as per the ARC definition as 
definite, possible or probable stent thrombosis [22].
 
Target lesion revascularisation was defined as any 
clinically indicated repeat percutaneous intervention of 
the target lesion or bypass surgery of the target vessel 
performed for restenosis or other complication of the 
target lesion. Major and minor bleeding was defined 
using the Thrombolysis in Myocardial Infarction (TIMI) 
bleeding criteria [22].
 
Obesity was defined as body 
mass index > 25 kg/m
2 
[23].  
 
Statistical analysis 
Descriptive analyses were performed. 
Categorical variables are expressed as number and 
percentage of patients. Continuous data are reported 
as mean ± SD.  
 
Results  
 
Baseline patient characteristics  
A total of 636 patients were enrolled in the 
study. Clinical follow-up was completed in 634 
(99.7%) patients at 30 days, 625 (98.2%) at 6 months, 
and 618 (97.1%) at 1 year, respectively. By the end of 
one year follow up 14 patients (2.2%) have died, and 
4 patients (0.6%) were lost to follow up. The patient 
follows up is presented in Figure 1. 
 
Figure 1: Patient flow and follow up through one year 
 
The mean age was 53.9 years, and 79% of 
the patients were male. There was a high prevalence 
of coronary risk factors including hypertension 
(57.6%), smoking (43.8%), dyslipidaemia (40.8%), 
obesity (36.9%) and diabetes (20.9%). 3.3% had 
suffered myocardial infarction before the index event, 
and 2.8% have earlier undergone PCI. Mean LVEF 
(left ventricular ejection fraction) was ~47%. 4.8% of 
patients presented in cardiogenic shock and 16.9% 
were in Killip class II or more. Baseline characteristics 
are shown in Table 1. 
Table 1: Baseline patient characteristics (N = 636) 
________________________________________________________________________ 
Age (years), mean ± SD                                                                     53.9 ± 11 
Male sex                                                                                            504 (79.2)  
BMI, mean ± SD                                                                                 26.5 ± 6.2 
Cardiovascular risk factors 
      Obesity                                                                                         235 (36.9) 
      Diabetes                                                                                       133 (20.9)  
       Hypertension                                                                               368 (57.6)  
       Dyslipidemia                                                                                260 (40.8)  
       Current smoker                                                                            279 (43.8)  
       Family history of CAD                                                                    82 (12.8) 
Prior MI                                                                                                 21 (3.3)  
Prior PCI                                                                                               18 (2.8)  
LVEF, mean ±SD                                                                                46.9 ± 6.2  
Cardiogenic shock                                                                              31 (4.8) 
Killip class >I                                                                                     108 (16.9) 
________________________________________________________________________ 
 
 
Lesion and procedural characteristics  
The mean door to balloon time was 56 
minutes. The radial approach was the primary route of 
angioplasty (96%). LAD/diagonal was the infarct-
related artery in half of the patients followed by RCA 
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(33%), and LMCA constituted 0.9% of the cases. The 
majority had single vessel disease (69%), and 6.6% 
had triple vessel disease. The mean diameter and 
mean length of the stent were 3.14 mm and 
26.15 mm, respectively. Multiple stents were used 
overall in 16% of patients before hospital discharge 
and in 4% of patients during the index procedure. 
Direct stenting was done in 67% of the patients. 
Thrombosuction was used in 3.3% patients, and bail-
out Gp IIb/IIIa inhibitor use was 10.5%. Clopidogrel 
(79%) was the most commonly prescribed DAPT (dual 
antiplatelet therapy) along with aspirin followed by 
ticagrelor (14%) and prasugrel (7%). Compliance to 
DAPT at one year was 94%. The device success rate 
was 99.3%, and the procedure success rate was 
98.1%. Lesion and procedural characteristics are 
summarized in Table 2. 
Table 2: Lesion and procedural characteristics (N = 636) 
________________________________________________________________________ 
Door to balloon (minutes), mean ± SD                                                     56 ± 11 
Radial access                                                                                         612 (96.2) 
Infarct related artery 
    Left main                                                                                                6 (0.94) 
    LAD/Diagonal                                                                                     309 (48.5) 
    LCX/Marginal                                                                                     108 (16.9)  
    RCA                                                                                                    213 (33.4)  
Multivessel disease                                                                                193 (30.3)  
Reference vessel diameter (mm), mean ±SD                                        2.91 ± 0.25 
Stented length (mm), mean ±SD                                                          26.15 ± 6.35  
Stent diameter (mm), mean ±SD                                                            3.14 ± 0.28 
Stent implanted per patient                                                                     1.18 ± 0.40 
Multiple stents used                                                                               102 (16) 
Thrombosuction                                                                                       21 (3.3) 
Direct stenting                                                                                        426 (66.9) 
Gp IIb/IIIa inhibitor use
*                                                                                                               
 67 (10.5) 
DAPT usage 
      Clopidogrel                                                                                           79% 
      Prasugrel                                                                                               7% 
      Ticagrelor                                                                                            14% 
DAPT compliance at 1-year                                                                      94% 
Device success                                                                                         99.3% 
Procedure success                                                                                   98.1% 
________________________________________________________________________ 
 
 
Clinical outcomes  
At one-year clinical follow-up, 14 patients 
(2.2%) had died, including 9 patients (1.4%) who died 
of cardiac reasons. The device oriented primary 
endpoint (DOCE) was seen in 1.1% at 30 days, 2% at 
6 months and 2.7% at the end of one year.  
Table 3: Clinical follow up 
________________________________________________________________________ 
        Outcomes                        30 days                         6 months                         1 year 
________________________________________________________________________ 
All death                                  3 (0.5)                            9 (1.4)                           14 (2.2)   
Cardiac de                               3 (0.5)                            7 (1.1)                             9 (1.4)   
MI (non-fatal)                           2 (0.3)                            4 (0.6)                             5 (0.8) 
Target vessel reinfarction       2 (0.3)                             3 (0.5)                             3 (0.5) 
Any revascularization             5 (0.8)                             9 (1.4)                           11 (1.7) 
TLR (clinical driven)                3 (0.5)                            5 (0.8)                             8 (1.2) 
Device oriented endpoint 
β        
7 (1.1)                          13 (2)                              18 (2.7) 
Patient oriented endpoint 
§
     9 (1.4)                          19 (3)                              26 (4.2) 
Stent thrombosis *                  3 (0.5)                            4 (0.6)                            4 (0.6) 
Definite                                   2 (0.3%)                         2 (0.3%)                         2 (0.3%) 
Probable                                1 (0.15%)                        2 (0.3%)                         2 (0.3%) 
Major and minor bleeding      3 (0.5)                             7 (1.1)                            9 (1.5) 
________________________________________________________________________ 
 
The patient-oriented co-primary endpoint 
(POCE) was 1.4%, 3% and 4.2% at 30 days, 6 
months and 1 year respectively. The target lesion re-
infarction at one year was 0.5%, and the clinical 
driven TLR rate was 1.2%. Definite and probable stent 
thrombosis occurred in 2 patients each till 6 months 
follow up (total 4 patients, 0.6%). Both of the definite 
stent thromboses were sub-acute (early stent 
thrombosis). Beyond 6 months no additional case of 
stent thrombosis was seen. The major and minor 
bleeding rates at one year were 1.5%. The clinical 
outcomes are detailed in Table 3. 
 
 
Discussion  
 
To our knowledge, this is the largest study 
reporting the real-world experience of biodegradable 
polymer sirolimus-eluting stent in the STEMI 
population undergoing primary angioplasty. This 
prospective, observational multicentric study showed 
excellent safety and efficacy profile of Yukon Choice 
PC Elite with low rates of POCE, DOCE, TLR and 
overall stent thrombosis rates at one year follow up. 
The study cohort had a high prevalence of 
cardiovascular risk factors, cardiogenic shock and 
poor Killip class, thereby reflecting real clinical 
practice and testing the stent in a real-world setting. 
This novel device with enhanced biocompatibility, 
therefore, appears to be an attractive option in the 
STEMI population. 
 The Yukon Choice PC stent (Translumina 
therapeutics, Hechingen, Germany) consists of a 
unique microporous stainless-steel stent surface 
coated abluminally with sirolimus and a PLA 
biodegradable polymer. This sirolimus-eluting BP-
DES has been found non-inferior to permanent 
polymer SES (Cypher) in the ISAR-TEST-3 study and 
permanent polymer EES (XIENCE V) or SES 
(Cypher) in ISAR-TEST-4 [13], [14].
 
Outcomes were 
non-inferior even at 3 years and 5 years follow up 
[24], [25]. The Yukon stent has also been shown to be 
non-inferior to the PES in diabetic patients (LIPSIA-
Yukon trial) [26], [27].
 
Furthermore, the ISAR-TEST 5 
trial showed that this strut had non-inferior results at 
one year and five years compared to a zotarolimus-
eluting stent [28], [29].
 
The Yukon Choice PC Elite 
uses the same stent platform and design as Yukon 
Choice PC used in the ISAR TEST 3 and 4 trials. The 
major difference is a temperature control system 
present with the current device, as sirolimus is 
temperature sensitive.  
 We have experienced high device and 
procedural success rate using the Yukon Elite stent 
(99.3% and 98.1% respectively). This is comparable 
to a procedural success rate of 97.5% using EES in 
EXAMINATION Trial [30]. All the operators in this 
study report to have experienced exceptional 
manoeuvrability, deliverability and flexibility during 
stent deployment. Direct stenting was done in 67%, 
and it failed in 5.6% patients, which is considerably 
lower than previously reported with 2
nd
 generation 
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DES (17-18%) [31], [32].
 
No case of failure of stenting, 
a mechanical complication related to stent or change 
over to different DES was seen. Given comparable 
efficacy of the contemporary DES, deliverability is 
certainly an important feature in relative superiority of 
stents. Unfortunately, deliverability data from 
randomised clinical trials are almost negligible, and 
therefore real-world experience is critical for 
determining relative deliverability. The excellent 
deliverability with Yukon Choice PC stent could be 
explained by widely spaced, thinner struts (87 µm) 
and newer improved stent delivery system. 
 There are limited studies comparing new-
generation DES (n-DES) and BMS in the STEMI 
population. In the recent two trials-COMFORTABLE 
AMI trial (biolimus-eluting stent with biodegradable 
polymer versus BMS) and EXAMINATION trial (EES 
versus BMS) in STEMI-new-generation DES were 
convincingly superior to BMS [30], [33].
 
Meta-analysis 
of these trials showed a significant reduction in rates 
of target vessel re-infarction, TLR and stent 
thrombosis in the DES arm [34].
 
Moreover, this benefit 
was extended up to 2-year follow-up in both trials [35], 
[36].
 
More recently, the 5-year follow-up of 
EXAMINATION trial demonstrated a reduction in the 
patient-oriented endpoints, device-oriented endpoints, 
stent thrombosis and all-cause mortality with DES 
[37].
 
Stenting with new-generation DES is thus 
recommended over BMS for primary PCI [2]. The 
results of the present study confirm these findings with 
a favourable 1-year safety and efficacy profile. The 
overall mortality at one year (2.2%) was lower as 
compared to COMFORTABLE AMI (3.2%) and 
EXAMINATION trial (3.5%), and the cardiac death too 
was much lower (1.4% vs 2.9% and 3.2% 
respectively). The DOCE in our study was 2.7% at 
one year as compared to 4.3% in COMFORTABLE 
AMI, and 5.5% EXAMINATION trial and the POCE 
was 4.2% vs 8.4% and 11.9% respectively.  
 The BP-DES were designed to confer benefit 
particularly in terms of late adverse events compared 
to durable polymer DES. This is especially applicable 
in STEMI, where the risk of stent thrombosis is 
increased due to high thrombus burden, increased 
platelet activation and inflammation leading to delayed 
endothelial healing. Indeed, in a pooled analysis of 
three trials in STEMI, BP-DES led to significant 
reduction in TLR rates and trend towards reduction of 
definite or probable stent thrombosis [38]. In our 
study, the overall stent thrombosis rate was 0.6% 
(definite 0.3% and or probably 0.3%), with no event 
seen beyond 6 months. This was lower compared to 
2.5% in COMFORTABLE AMI trial and 0.9% in 
EXAMINATION trial [30], [33]. In ISAR-5 trial, the 
incidence of definite/probable stent thrombosis was 
1.1% in BPDES group and 1.2% in Zotarolimus arm at 
one year, and there was no stent thrombosis seen 
beyond one year [29]. Similarly, in COMFORTABLE 
AMI trial, there was no case of late definite stent 
thrombosis [35].  
Study limitations 
The strength of this study was a prospective 
design with a large number of STEMI patients from 
multiple centres. However, there were several 
important limitations too. First, it was an observational 
study, and a head-to-head comparison is required to 
confirm the safety and efficacy relative to other newer 
generation DES. Second, the limited follow up of one 
year does not allow capturing of very late stent 
thrombosis. However, recent studies with longer 
follow up in the STEMI population didn’t show any 
stent thrombosis beyond one year [29], [35]. Third, 
there may have been underreporting of MI and TLR 
as follow-up angiography, and routine cardiac bio-
marker estimation was not mandatory. However, 
asymptomatic MI and restenosis are usually 
associated with less clinical significance, and it is 
unlikely that they would have affected the final results 
of this study. 
Furthermore, the excellent follow-up results 
represent indirect evidence of favourable effects of the 
stent used in the study. Fourth, the favourable results 
in our study may have been influenced by a greater 
proportion of direct stenting, shorter door-balloon time, 
experienced operators, predominantly radial approach 
and selective use of thrombosuction. Finally, there are 
reports to suggest that the incidence of stent 
thrombosis is relatively low in Asian populations [39] 
and thereby the results may not apply to other 
populations.  
In conclusion, in patients with STEMI 
undergoing primary angioplasty, the use of Yukon 
Choice PC Elite (biodegradable polymer sirolimus-
eluting stent) has excellent safety and efficacy profile 
at one year. It may, therefore, represent an attractive 
solution in this high-risk population. However, long-
term follow is needed to determine safety in terms of 
very late adverse events.  
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